收费全文 | 656篇 |
免费 | 29篇 |
国内免费 | 61篇 |
耳鼻咽喉 | 4篇 |
儿科学 | 24篇 |
妇产科学 | 6篇 |
基础医学 | 74篇 |
口腔科学 | 25篇 |
临床医学 | 83篇 |
内科学 | 120篇 |
皮肤病学 | 11篇 |
神经病学 | 25篇 |
特种医学 | 86篇 |
外科学 | 63篇 |
综合类 | 24篇 |
一般理论 | 1篇 |
预防医学 | 70篇 |
眼科学 | 12篇 |
药学 | 87篇 |
中国医学 | 1篇 |
肿瘤学 | 30篇 |
2021年 | 9篇 |
2019年 | 7篇 |
2018年 | 13篇 |
2017年 | 9篇 |
2016年 | 7篇 |
2015年 | 15篇 |
2014年 | 16篇 |
2013年 | 28篇 |
2012年 | 9篇 |
2011年 | 11篇 |
2010年 | 21篇 |
2009年 | 24篇 |
2008年 | 7篇 |
2007年 | 48篇 |
2006年 | 22篇 |
2005年 | 19篇 |
2004年 | 13篇 |
2003年 | 11篇 |
2002年 | 12篇 |
2001年 | 16篇 |
2000年 | 15篇 |
1999年 | 16篇 |
1998年 | 31篇 |
1997年 | 37篇 |
1996年 | 28篇 |
1995年 | 24篇 |
1994年 | 12篇 |
1993年 | 24篇 |
1992年 | 4篇 |
1991年 | 12篇 |
1990年 | 10篇 |
1989年 | 21篇 |
1988年 | 14篇 |
1987年 | 14篇 |
1986年 | 11篇 |
1985年 | 16篇 |
1984年 | 16篇 |
1983年 | 9篇 |
1982年 | 6篇 |
1981年 | 8篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1975年 | 5篇 |
1974年 | 9篇 |
1973年 | 11篇 |
1972年 | 4篇 |
1968年 | 4篇 |
1966年 | 4篇 |
BACKGROUND AND PURPOSE
Conditioned gaping reactions reflect nausea-induced behaviour in rats. Cannabinoid 1 receptor (CB1) agonists interfere with the establishment of nausea-induced conditioned gaping; however, it is not known if their effects are mediated by an action at peripheral or central CB1 receptors.EXPERIMENTAL APPROACH
We utilized the conditioned gaping model of nausea to evaluate the effect of peripheral and central administration of the peripherally restricted CB1 agonist, CB13, on the establishment of LiCl-induced gaping in rats. We further evaluated the ability of HU-210 administered to the gustatory insular cortex (GIC) or visceral insular cortex (VIC) to interfere with LiCl-induced conditioned gaping and determined if this effect was mediated by CB1 receptors.KEY RESULTS
Central, but not peripheral, CB13 suppressed LiCl-induced conditioned gaping. Central administration of the potent CB1 agonist, HU-210, delivered to the VIC, but not the GIC, suppressed the establishment of LiCl-induced gaping reactions, but not LiCl-induced suppression of hedonic reactions or conditioned taste avoidance. This pattern of results suggests that HU-210 delivered to the VIC prevented LiCl-induced nausea, but not learning per se. The suppression of LiCl-induced conditioned gaping by HU-210 was mediated by CB1 receptors because it was prevented by co-administration of CB1 antagonist/inverse agonist, AM-251, into the VIC. A high dose of AM-251 (20 µg) administered alone into the VIC did not produce conditioned gaping reactions.CONCLUSIONS AND IMPLICATIONS
The nausea-relieving effects of CB1 agonists, but not the nausea-inducing effects of CB1 inverse agonists, are mediated, at least in part, by their action at the VIC in rats. 相似文献Areas covered: We discuss aberrant lipid metabolism and the promise of multiple targets, in particular related to HCC treatment. We searched PubMed and clinicaltrials.gov for published and unpublished studies from 2000 to 2019. These terms were used: lipids, fatty acid metabolism, lipid metabolism, liver cancer, HCC, de novo fatty acid synthesis, ATP citrate lyase, stearoyl CoA denaturase, fatty acid synthase, acetyl coenzyme A carboxylase, CD147, KLF4, monoglyceride lipase, AMP activated protein kinase.
Expert opinion: The importance of dysregulation of fatty acid synthesis in cancer is a growing area of research. HCC demonstrates significant alteration in lipid metabolism, representing great potential as a target for novel therapeutics. Various agents have demonstrated promising anti-neoplastic activity. This strategy deserves further development for improved outcomes. 相似文献
Areas covered: In this review, the current standard of care in immunosuppressive therapy, including the use of steroids, calcineurin inhibitors, mycophenolate prodrugs and mammalian target of rapamycin inhibitors, will be discussed. Newer immunosuppressive agents showing promising early data after liver and kidney transplantation will also be explored.
Expert Opinion: Currently, calcineurin inhibitors continue to be a vital component of immunosuppressive therapy after solid organ transplantation. Although minimization and avoidance strategies have been developed, the ultimate goal of inducing tolerance remains elusive. Newer emerging agents should have potent and specific immunosuppressive activity, with minimal associated side effects. An individualized approach should be adopted to tailor immunosuppression according to the different needs of recipients. 相似文献